

TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

9/9/2020; Page 1

Suggested Formula	Methyldopa 250 mg Oral Capsules (Powder Blend, 100 x Size #0 Capsules)	FIN	F 008 921
----------------------	--	-----	-----------

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Methyldopa, USP	TBD					
Medisca CapsuBlend®-H	TBD					
Sodium Chloride, USP	As required					

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information

Light Sensitive (protect from light whenever possible): Methyldopa

Hygroscopic (protect from moisture whenever possible): Methyldopa, CapsuBlend®-H



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

9/9/2020; Page 2

Suggested Formula	Methyldopa 250 mg Oral Capsules (Powder Blend, 100 x Size #0 Capsules)	FIN	F 008 921
----------------------	--	-----	-----------

SPE

CIAL PREPARATORY CONSI	DERATIONS (CONTINUED)
Suggested Preparatory Guidelines	
Non-Sterile Preparat	ion Sterile Preparation
<u>Processing Error /</u> <u>Testing Considerations</u> :	To account for processing error considerations during preparation, it is suggested to measure an additional 5 to 9% of the required quantities of ingredients.
Special Instruction:	This formula may contain one or more Active Pharmaceutical Ingredients (APIs) that may be classified as hazardous, please refer & verify the current NIOSH list of Antineoplastic and Other Hazardous Drugs in Healthcare Settings. At this time, General Chapter <800> Hazardous Drugs – Handling in Healthcare Settings is informational and not compendially applicable unless otherwise specified by regulators and enforcement bodies. For information on the scope, intended applicability, and implementation context for USP General Chapter <800>, see: https://www.usp.org/compounding/general-chapter-hazardous-drugs-handling-healthcare .
	This formula must be prepared within the appropriate facilities under adequate environmental conditions, following the necessary guidelines and procedures as stated within <i>USP 795</i> and <i>USP 800</i> , when handling hazardous drugs. Only trained and qualified personnel must prepare this formula. All required personal protective equipment (hazardous if applicable), such as but not limited to, lab coat, protective sleeves, gloves both inner and outer if applicable, dedicated shoe covers, hairnet, beard cover, eyewear, appropriate face mask, respirator and face shield, etc., where applicable must be worn at all times.
	If applicable, follow all required procedures for hazardous drug handling including but not limited to procurement, transport, storage, preparation, dispensing, administration, clean up (spills) & disposal.
	If you are a registered 503B facility, please refer to all relevant guidance documents including but not limited to the Code of Federal Regulations (CFR), Guidance for Industry (GFIs) and Compliance Policy Guides (CPGs).
	This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

9/9/2020; Page 3

Suggested Formula	Methyldopa 250 mg Oral Capsules (Powder Blend, 100 x Size #0 Capsules)	FIN	F 008 921
----------------------	--	-----	-----------

SUGGESTED PREPARATION (for 100 Size #0 Capsules)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*):	Processing Error	Qty. to measure
Methyldopa, USP§	TBD				
Medisca CapsuBlend®-H §	TBD				
Sodium Chloride, USP	As required		©		

- * Takes into account increased batch size conversions and density conversions, if required.
- § Weigh / measure just prior to use.



MEDISCA® NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT

TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

9/9/2020; Page 4

Suggested Formula Methyldopa 250 mg Oral Capsules (Powder Blend, 100 x Size #0 Capsules)

FIN F 008 921

A. Determine the potency of Methyldopa based on the certificate of analysis:	
	100%
MINUS	
Water Content (from certificate of analysis)	
DIVIDED BY	100
EQUALS	
Quantity of water free Methyldopa, in decimal	
MULTIPLIED BY	
Assay on anhydrous basis result (from certificate of analysis)	
DIVIDED BY	100
EQUALS	



MULTIPLIED BY

EQUALS

Processing error adjustments (5 to 9%)

MEDISCA® NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811

TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

ii. Quantity of Methyldopa needed plus processing error adjustments

9/9/2020; Page 5

1.05 to 1.09

_	ggested ormula	Methyldopa 250 mg Oral Capsules (Powder Blend, 100 x Size #0 Capsules)	FIN	F 008 921
2.	Ingro	edient quantification:		
	А. Г	Determine the quantity (in g) of Methyldopa required to make 100 Capsules of Methyldo	pa 250	mg:
		Quantity of Methyldopa needed for each capsule	0	0.250 g
	I	DIVIDED BY		
	F	Potency of Methyldopa, in decimal (Step 1Ai)	-	
	E	EQUALS		
	i.	Actual Quantity of Methyldopa needed for each capsule	_	g
	N	MULTIPLIED BY		
	N	Number of capsules		100



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

9/9/2020; Page 6

Suggested Formula	Methyldopa 250 mg Oral Capsules (Powder Blend, 100 x Size #0 Capsules)	FIN	F 008 921
----------------------	--	-----	-----------

3.

4. CapsuBlend®-H requirements for 100 x Size #0 Capsules

A. Calculate the amount of CapsuBlend®-H required for the batch. Refer to attached appendix for details.

5. **Powder preparation:**

- A. By geometric addition, combine and triturate the following ingredients together:
 - -Methyldopa (amount determined in Step 2Aii)
 - -CapsuBlend®-H (Quantity determined in appendix (I))

End result: Homogeneous powder blend.

6. **Product transfer:**

Fill each of 100 Size #0 capsules with the powder blend (Step 5A). Close each capsule tightly.

Clean each capsule by placing the capsules in a container filled with Sodium chloride, and then gently rolling the container. Pour the container contents into a 10-mesh sieve, and allow the Sodium chloride to pass through. Finally, roll the capsules on a cloth-covered surface.

7. Validation technique:

The final weight of each capsule (not including capsule shell) should fall between 90 and 110% of the theoretically calculated weight, in accordance to USP 795 guidelines. The theoretically calculated weight can be determined by adding the following values: **Step 2Ai** + the amount in appendix **(G)**.

8. **Product transfer:**

Transfer the final product into the specified dispensing container (see "Packaging Requirements").



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

9/9/2020; Page 7

Suggested Formula	Methyldopa 250 mg Oral Capsules (Powder Blend, 100 x Size #0 Capsules)	FIN	F 008 921
----------------------	--	-----	-----------

SUGGESTED PRESENTATION

JOGESTEE	D 1 1 1 1 1	-01	MIAHON			
Estimated Beyond-Use Date			6 months, as per USP 795*.	Packa Requiren		Tightly closed, light-resistant capsule shells and vials.
		1	Use as directed. Do not exceed dose.	d prescribed	5	Keep in a dry place.
		2	Keep out of reach of children.		6	Protect from light.
	iliary abels	3	Consult your health care practite other prescription or over medications are currently being prescribed for future use.	-the-counter	7	Cap tightly after use.
		4	Keep at controlled room temper – 25°C).	rature (20°C		
Pharm Instruct		Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.				
Pa Instruct	atient tions	Contact your pharmacist in the event of adverse reactions.				

^{*} The BUD is not later than the time remaining until the earliest expiration date of any API or 6 months, whichever is earlier.

REFERENCES

1.	Capsules. In: Allen, LV, Jr. <i>The Art, Science, and Technology of Pharmaceutical Compounding Fifth Edition.</i> American Pharmacists Association; 2016: 189.
2.	Sodium Chloride. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients</i> , 7 th Edition. American Pharmaceutical Association; 2012: 729.
3.	Methyldopa. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference</i> , 38th Edition. London, England: The Pharmaceutical Press; 2020: 1431.
4.	Methyldopa (Monograph). <i>United States Pharmacopeia XLIII / National Formulary 38</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2020: 2877.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

9/9/2020; Page 8

S	uggested Formula	Methyldopa 250 mg Oral Capsules (Powder Blend, 100 x Size #0 Capsules)	FIN	F 008 921		
5.	Methyldopa (Monograph). In: O'Neil MJ. <i>The Merck Index 15th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2013: Monograph #6127.					
6.	USP <795>. United States Pharmacopeia XLIII/ National Formulary 38. Rockville, MD. US Pharmacopeial Convention, Inc. 2020: 7025.					



DISCLAIMER: THIS DOCUMENT IS COPYRIGHT© 2020 MEDISCA PHARMACEUTIQUE INC. MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY, SCHEDULING OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW. MEDISCA NETWORK INC. MAKES NO WARRANTIES WITH RESPECT TO INFRINGEMENT OR NON-INFRINGEMENT BY THE FORMULA OF ANY PATENT OR OTHER INTELLECTUAL PROPERTY OF ANY OTHER PARTY, AND IT IS THE RESPONSIBILITY OF THE PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL TO INVESTIGATE AND DETERMINE ANY SUCH ISSUE.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

Suggested Formula	Calculating the quantity of excipient required for the batch		
----------------------	--	--	--

	Procedure
1.	Capsule filling:
	a. For <u>each</u> ingredient powder below, determine the average capsule fill weight by filling and weighing five TARED CAPSULES. Do not forget to divide the total weight by 5 to obtain an <u>average</u> capsule fill weight. Also, triturate the ingredient powder first if required in formulation.
	Plug each amount into Step 2, column B.
2.	Volume Percent Occupied: Column A Column B Column C
	Quantity Required Average capsule A/B x 100 equals Ingredients per capsule fill weight percent filled
	a. Methyldopa (Step 2Ai) from main formula g g %
	b. CapsuBlend®-Hg
	c. Total (add column C together) % (D)
3.	Calculate the quantity of CapsuBlend®-H required for the batch:
	a. Percent of CapsuBlend®-H required = 100% – (D)% (E)
	b. Average capsule fill weight of CapsuBlend®-H (from column B, Step 2b): g (F)
	c. Quantity of CapsuBlend®-H required per capsule = $[(E) \div 100 \times (F)]$ g (G)
	d. Total quantity of CapsuBlend®-H required for the batch = $100 \text{ capsules} \times (G)$ g (H)
	e. Total quantity of CapsuBlend®-H plus processing error = $(H) \times 1.05-1.09$ g (I)

DISCLAIMER: THIS DOCUMENT IS COPYRIGHT© 2020 MEDISCA PHARMACEUTIQUE INC. MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY, SCHEDULING OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL TO KNOW THE LAW, MEDISCA NETWORK INC. MAKES NO WARRANTIES WITH RESPECT TO INFRINGEMENT OR NON-INFRINGEMENT BY THE FORMULA OF ANY PATENT OR OTHER INTELLECTUAL PROPERTY OF ANY OTHER PARTY, AND IT IS THE RESPONSIBILITY OF THE PHARMACIST OR OTHER APPROPRIATELY STATE LICENSED PROFESSIONAL TO INVESTIGATE AND DETERMINE ANY SUCH ISSUE.